UNSPSC 51393303: Clonazoline

This classification denotes an alpha-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YH9K692U9S. European Medicines Agency schedules Clonazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06729MIG. Clonazoline generally arises in the molecular formula C14H13CLN2.

UNSPSC 51393303 Clonazoline is a Commodity code that describes pharmaceutical products, but the recent state and local opportunities tagged under it show procurement of naloxone and drug deactivation systems for emergency response and harm-reduction purposes, along with exploratory contracting for direct-to-manufacturer pharmacy programs. State and local governments buying under this code are acquiring emergency medical countermeasures and exploring alternative pharmacy supply-chain models to reduce costs and improve fulfillment efficiency. Issuing bodies include county health departments and state health and human services commissions. The work spans both commodity purchases of naloxone and related systems and strategic sourcing initiatives for prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity appears primarily in Florida and Texas. Seminole County, Florida released IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a bid deadline of July 26, 2023 and fixed-fee pricing; the contract carries a two-year initial term with one-year renewal option and potential FEMA funding. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to solicit vendor capabilities for implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information on vendors' experience with direct contracting for self-insured employers and state agencies and their flexibility to negotiate net-pricing models without rebates. Neither solicitation specifies explicit set-aside designations. The mismatch between the code name (clonazoline) and actual procurement scope (naloxone and pharmacy supply-chain programs) suggests the code may be broadly applied or mistagged in state and local systems.